SLP logo

Simulations Plus (SLP) Company Overview

Profile

Full Name:

Simulations Plus, Inc.

Sector:

Healthcare

Country:

United States

IPO:

June 18, 1997

Indexes:

Not included

Description:

Simulations Plus, Inc. is one of the leading developers of software used for modeling and simulation in drug development and research. The company was founded in 1996. The headquarters is located in Lancaster, California (USA). Simulations Plus, Inc. has developed the following software products for pharmaceutical research and development: Modeling programs: GastroPlus; DDDPlus; MembranePlus; DILIsym, NAFLDsym. Programs based on forecasting and analysis of chemical properties: ADMET Predictor; MedChem Designer; MedChem Studio. PKPlus program designed for rapid analysis of clinical trial data and submission of regulatory documents. KIWI program providing an integrated platform for data analysis and reporting through its own secure cloud.

Key Details

Price

$35.09

Annual Revenue

$70.01 M(+17.52% YoY)

Annual EPS

$0.49(0.00% YoY)

Beta

1.01

Events Calendar

Earnings

Next earnings date:

Apr 3, 2025

Recent quarterly earnings:

Jan 7, 2025

Recent annual earnings:

Oct 23, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jul 29, 2024
Splits

Next split:

N/A

Recent split:

Oct 2, 2007

Analyst ratings

Recent major analysts updates

Jan 24, 25 Keybanc
Overweight
Jan 8, 25 Keybanc
Overweight
Nov 15, 24 Stephens & Co.
Overweight
Nov 6, 24 William Blair
Outperform
Oct 24, 24 William Blair
Outperform
Oct 24, 24 BTIG
Buy
Sep 12, 24 William Blair
Outperform
Jul 29, 24 Keybanc
Overweight
Jul 16, 24 JMP Securities
Market Perform
Jul 3, 24 Craig-Hallum
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
SLP
businesswire.comJanuary 22, 2025

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function.

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
SLP
businesswire.comJanuary 13, 2025

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.

Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y
Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y
Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y
SLP
zacks.comJanuary 8, 2025

SLP's fiscal first-quarter performance is driven by healthy revenue growth across its Software segment and contributions from the acquisition of Pro-ficiency.

Simulations Plus (SLP) Lags Q1 Earnings Estimates
Simulations Plus (SLP) Lags Q1 Earnings Estimates
Simulations Plus (SLP) Lags Q1 Earnings Estimates
SLP
zacks.comJanuary 7, 2025

Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago.

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
SLP
businesswire.comJanuary 7, 2025

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenu.

Simulations Plus Gears Up for Q1 Earnings: What's in Store?
Simulations Plus Gears Up for Q1 Earnings: What's in Store?
Simulations Plus Gears Up for Q1 Earnings: What's in Store?
SLP
zacks.comJanuary 6, 2025

SLP's fiscal first quarter performance is likely to have gained from strength in both Software and Services' segments.

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
SLP
businesswire.comDecember 17, 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investm.

Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
SLP
zacks.comNovember 22, 2024

Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth
Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth
Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth
SLP
zacks.comOctober 24, 2024

SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
SLP
seekingalpha.comOctober 23, 2024

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript

FAQ

  • What is the ticker symbol for Simulations Plus?
  • Does Simulations Plus pay dividends?
  • What sector is Simulations Plus in?
  • What industry is Simulations Plus in?
  • What country is Simulations Plus based in?
  • When did Simulations Plus go public?
  • Is Simulations Plus in the S&P 500?
  • Is Simulations Plus in the NASDAQ 100?
  • Is Simulations Plus in the Dow Jones?
  • When was Simulations Plus's last earnings report?
  • When does Simulations Plus report earnings?
  • Should I buy Simulations Plus stock now?

What is the ticker symbol for Simulations Plus?

The ticker symbol for Simulations Plus is NASDAQ:SLP

Does Simulations Plus pay dividends?

Yes, Simulations Plus pays dividends. The last payment was $0.06, with an ex-dividend date on July 29, 2024

What sector is Simulations Plus in?

Simulations Plus is in the Healthcare sector

What industry is Simulations Plus in?

Simulations Plus is in the Health Information Services industry

What country is Simulations Plus based in?

Simulations Plus is headquartered in United States

When did Simulations Plus go public?

Simulations Plus's initial public offering (IPO) was on June 18, 1997

Is Simulations Plus in the S&P 500?

No, Simulations Plus is not included in the S&P 500 index

Is Simulations Plus in the NASDAQ 100?

No, Simulations Plus is not included in the NASDAQ 100 index

Is Simulations Plus in the Dow Jones?

No, Simulations Plus is not included in the Dow Jones index

When was Simulations Plus's last earnings report?

Simulations Plus's most recent earnings report was on Jan 7, 2025

When does Simulations Plus report earnings?

The next expected earnings date for Simulations Plus is Apr 3, 2025

Should I buy Simulations Plus stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions